BioCryst Pharmaceuticals BCRX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| Collaborative and other revenues | $2M+14.3% | $3.38M+54.1% | $1.66M+62.9% | $923K-31.4% | $1.75M-49.9% | |
| License and other revenues | $5.01M+187% | —— | —— | —— | $1.75M-13.1% | |
| ORLADEYO | $148.35M+10.5% | $151.68M+22.1% | $159.08M+36.8% | $156.84M+44.8% | $134.24M+51.1% | |
| Other revenues | $5.05M-55.3% | $10.89M+48.2% | $318K-58.5% | $6.52M+524% | $11.29M+190% | |
| Product sales, net | $151.4M+5.3% | $159.2M+23.1% | $157.74M+35.9% | $162.43M+50.4% | $143.79M+61.1% | |
| Total trade receivables by Product | ||||||
| License and other revenues | $6.6M— | $3.98M— | —— | —— | —— | |
| ORLADEYO | $102.29M+13.0% | $92.35M+21.1% | $88.03M+23.9% | $87.58M+32.1% | $90.49M+60.4% | |
| Peramivir | $381K-68.3% | $10.49M+1,760% | $153K— | $381K— | $1.2M— | |
| Contract with customer, transaction price by Product | ||||||
| License and other revenues | $2.4M— | —— | —— | —— | —— | |
| Research and Development | $20.67M— | —— | —— | —— | —— | |
| Research and Development Expense (Excluding Acquired in Process Cost) by Product | ||||||
| Avoralstat | $893K-64.0% | —— | —— | —— | $2.48M— | |
| BCX17725 | $1.91M-22.4% | —— | —— | —— | $2.46M— | |
| Berotralstat | $1.8M-4.2% | —— | —— | —— | $1.87M— | |
| Compensation and related personnel costs | $27.09M+119% | —— | —— | —— | $12.34M— | |
| Navenibart | $9.74M— | —— | —— | —— | $0— | |
| Other non-program specific and indirect costs | $7.42M+13.3% | —— | —— | —— | $6.55M— | |
| Research, discovery and preclinical programs | $3.97M+30.4% | —— | —— | —— | $3.04M— | |
| STAR-0310 | $683K— | —— | —— | —— | $0— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does BioCryst Pharmaceuticals break its business down?
- BioCryst Pharmaceuticals (BCRX) reports total revenues by product across 5 parts — Collaborative and other revenues, License and other revenues, ORLADEYO, Other revenues and Product sales, net. Each is extracted from the segment footnotes and tracked over time.
- Where does BioCryst Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in BioCryst Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
